|Dr. Jay R. Luly||Pres, CEO & Director||867.84k||N/A||1956|
|Mr. Paul J. Mellett Jr.||Sr. VP-Fin. & Admin., CFO and Principal Accounting Officer||513.18k||N/A||1955|
|Dr. Yat Sun Or||Sr. VP-R&D and Chief Scientific Officer||564.64k||N/A||1952|
|Dr. Nathalie Adda||Sr. VP & Chief Medical Officer||N/A||N/A||1966|
|Mr. Nathaniel S. Gardiner J.D.||Sr. VP, Gen. Counsel & Sec.||N/A||N/A||1954|
Enanta Pharmaceuticals, Inc., a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus. It has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.
Enanta Pharmaceuticals, Inc.’s ISS Governance QualityScore as of March 1, 2018 is 5. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 8; Compensation: 6.